chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Pyrexia, Urticaria
Clinical narrative: Fever; Left arm hurts; Large red itchy bump; Swollen lymph nodes hurt under left arm; Very tired; Flu-like symptoms; Chills; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 10Apr2021 at 09:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not take any concomitant medications. The patient previously took cefprozil (CEFZIL) and azithromycin (Z-Pack) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration on an unknown date in 2021 as a single dose for COVID-19 immunisation.  On 10Apr2021 at 22:00, the patient experienced chills, left arm hurts, large red itchy bump, swollen lymph nodes hurt under left arm, very tired and flu-like symptoms. On 11Apr2021, the patient experienced fever. The patient reported that, the chills started 13 hours after the injections and did not sleep during the night. She had fever of 39.7C, started after 26 hours of injection and took paracetamol after 26 hours of injection. She stated it took 2 days to go back to 37C. She also experienced left arm hurts, large red itchy bump, swollen lymph nodes hurt under left arm for 5 days, very tired and flu-like symptoms for 3 days. Therapeutic measures were taken as a result of fever and included treatment with paracetamol (MANUFACTURER UNKNOWN) from 11Apr2021 and unknown if ongoing. On 11Apr2021, the patient underwent body temperature test and the result was 39.7centigrade. On 13Apr2021, the patient underwent body temperature test and the result was 37 centigrade. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever was resolved on 13Apr2021, after a duration of 2 days; while that of the events very tired and flu-like symptoms were resolved on 13Apr2021, after a duration of 3 days. The clinical outcome of the event swollen lymph nodes hurt under left arm was resolved 15Apr2021, after a duration of 5 days; while that of the events chills left arm hurts and large red itchy bump were resolved on an unspecified date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Myalgia, Pain, Pyrexia
Clinical narrative: high fever,; aches; Muscle pain; No energy for over five days; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the right arm on 02Mar2021 at 11:00 (at the age of 66-year-old) as a single dose for COVID-19 immunisation. Medical history included lymphoma, and COVID-19. Concomitant medications included valsartan (MANUFACTURER UNKNOWN), pravastatin (MANUFACTURER UNKNOWN), vitamin D nos (VITAMIN D) and biotin (MANUFACTURER UNKNOWN); all were taken from an unknown date for unspecified indication and unknown if ongoing. The patient previously received erythromycin (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient did not received any other vaccine with in four weeks prior to vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 03Mar2021 at 00:15, the patient experienced high fever, aches/muscle pain, no energy for over five  days. Therapeutic measures were not taken as a result of the events. Since the vaccination the patient was not tested for COVID-19. The clinical outcome of the event high fever, aches/muscle pain, no energy for over five days was resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Nausea, Oropharyngeal pain, Parosmia, Taste disorder
Clinical narrative: Cough; Sore throat; Nausea; Distorted taste and smell; Distorted taste and smell; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 19Apr2021 at 13:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6201) via an unspecified route of administration in the right arm on 31Mar2021 at 12:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. On 19Apr2021 the patient experienced cough, sore throat, nausea and distorted taste and smell. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events cough, sore throat, nausea was resolved on an unknown date in Apr2021; while that of distorted taste and smell was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: Left rotator soreness; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EJ1685) via an unspecified route of administration in the left arm on 18Dec2020 at 09:30 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and thyroid cancer. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had received concomitant medications which were not specified within two weeks of vaccination for unknown indication on unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021, the patient experienced left rotator soreness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event left rotator soreness was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Photophobia, Vision blurred
Clinical narrative: Blurred vision; Sensitivity to light; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the right arm on 19Apr2021 at 13:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) for unknown indication from unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 27Mar2021 at 13:00 as a single dose for COVID-19 immunisation. On 22Apr2021, the patient experienced blurred vision and sensitivity to light. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event blurred vision and sensitivity to light was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Eye pain, Headache
Clinical narrative: Constant nagging headache on the left side of the head with eye pain; Constant nagging headache on the left side of the head with eye pain; Pain on the left side of the chest; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 15Apr2021 at 10:30 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included depression, anxiety and bipolar 2. It was unknown if the patient had any known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included amfetamine aspartate/amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (ADDERALL), buspirone (MANUFACTURER UNKNOWN), trazodone (MANUFACTURER UNKNOWN) and lamotrigine (MANUFACTURER UNKNOWN); all for unknown indications from unknown dates and unknown if ongoing. On 17Apr2021 at 12:00, the patient experienced constant nagging headache on the left side of the head with eye pain and pain on the left side of the chest. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown if any therapeutic measures were taken for the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events constant nagging headache on the left side of the head with eye pain and pain on the left side of the chest was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Blepharospasm
Clinical narrative: Persistent right eyelid muscle spasms. After 2 weeks, both eyes spasm. Alternating, severity increases in bright environments or while standing.; This is a spontaneous report from a contactable consumer. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 31Mar2021 at 16:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 16:00, the patient experienced persistent right eyelid muscle spasms. After 2 weeks, the patient experienced both eyes spasm, alternating, severity increased in bright environments or while standing. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event persistent right eyelid muscle spasms, after 2 weeks, both eyes spasm, alternating, severity increased in bright environments or while standing was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Myalgia
Clinical narrative: Headache; Fatigue; Muscle aches; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an intramuscular route of administration in the left arm on 26Apr2021 at 12:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the vaccination. Concomitant medications included paroxetine (MANUFACTURER UNKNOWN) and bupropion (MANUFACTURER UNKNOWN); for unknown indication from an unknown date and unknown if ongoing. The patient previously took cefaclor (CECLOR) and amoxicillin / clavulanic acid (AUGMENTIN) for unknown indication on unknown date and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an intramuscular route of administration in the left arm on 29Mar2021 at 15:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. On 27Apr2021 at 12:00, the patient experienced headache, fatigue, muscle aches. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, fatigue, muscle aches was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Heart rate increased, Hypoaesthesia, Paraesthesia, Pruritus
Clinical narrative: Slight itchiness, but not numbness on upper lip area and lip line and nostrils; Slight itchiness, but not numbness the next day (today) on upper lip area and lip line and nostrils with 99.4F temp; Slight tingly/numb or dullness in face (forehead and cheeks) and maybe finger tips; Slight tingly/numb or dullness in face (forehead and cheeks) and may be finger tips; Raised heart rate in the evening; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 26Apr2021 at 09:15 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergy to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included lamotrigine (MANUFACTURER UNKNOWN) and ethinylestradiol/levonorgestrel (CHATEAL); both for unknown indications from unknown dates and unknown if ongoing. The patient previously received sertraline hydrochloride (ZOLOFT) on an unknown date for an unknown indication and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EE0151) via an unspecified route of administration in the left arm on 05Apr2021 at 09:00 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Apr2021 at 17:00, about 7 hours after shot, the patient experienced slight tingly/numb or dullness in face (forehead and cheeks) and maybe finger tips and raised heart rate in the evening. On 27Apr2021, next day of vaccination, the patient experienced slight itchiness, but not numbness on upper lip area and lip line and nostrils with 99.4 degrees Fahrenheit temperature. On 27Apr2021, the patient underwent lab test which included body temperature test and the result was found to be 99.4 degrees Fahrenheit. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events slight tingly/numb or dullness in face (forehead and cheeks) and may be finger tips, raised heart rate, slight itchiness, but not numbness on upper lip area and lip line and nostrils with 99.4 degrees Fahrenheit temperature were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Slight itchiness, but not numbness on upper lip area and lip line and nostrils; Slight itchiness, but not numbness the next day (today) on upper lip area and lip line and nostrils with 99.4F temp; Slight tingly/numb or dullness in face (forehead and cheeks) and maybe finger tips; Slight tingly/numb or dullness in face (forehead and cheeks) and may be finger tips; Raised heart rate in the evening; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 26Apr2021 at 09:15 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergy to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included lamotrigine (MANUFACTURER UNKNOWN) and ethinylestradiol/levonorgestrel (CHATEAL); both for unknown indications from unknown dates and unknown if ongoing. The patient previously received sertraline hydrochloride (ZOLOFT) on an unknown date for an unknown indication and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EE0151) via an unspecified route of administration in the left arm on 05Apr2021 at 09:00 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Apr2021 at 17:00, about 7 hours after shot, the patient experienced slight tingly/numb or dullness in face (forehead and cheeks) and maybe finger tips and raised heart rate in the evening. On 27Apr2021, next day of vaccination, the patient experienced slight itchiness, but not numbness on upper lip area and lip line and nostrils with 99.4 degrees Fahrenheit temperature. On 27Apr2021, the patient underwent lab test which included body temperature test and the result was found to be 99.4 degrees Fahrenheit. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events slight tingly/numb or dullness in face (forehead and cheeks) and may be finger tips, raised heart rate, slight itchiness, but not numbness on upper lip area and lip line and nostrils with 99.4 degrees Fahrenheit temperature were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Heavy menstrual bleeding
Clinical narrative: Extremely heavy menstrual flow, much heavier than what is normal for me.; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 20Apr2021 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 25Apr2021, the patient experienced extremely heavy menstrual flow, much heavier than what was normal for the patient. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event extremely heavy menstrual flow was resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Fatigue, Gingival blister, Gingival swelling, Lymphadenopathy
Clinical narrative: Extreme nausea; Exhaustion; Swollen lymph nodes in neck; Swollen gums; Swollen gums that later blistered; Swollen tongue; Swollen tongue that blistered; Oral thrush; Sore muscles; No energy; Fatigue; Sore throat; Sore arm at injection site; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0162) via an unspecified route of administration in the left arm on 21Apr2021 at 13:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included stevens johnson syndrome. The patient had no known allergies. Concomitant medications included amfetamine aspartate/ amfetamine sulfate/ dexamfetamine saccharate/ dexamfetamine sulfate (ADDERALL), paracetamol (TYLENOL) and vitamins (MANUFACTURER UNKNOWN) (unspecified); all from unknown dates for unknown indications and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, the patient experienced sore arm at injection site and had no symptoms for 48 hours after the vaccination. After 48 hours, on 23Apr2021, the patient experienced swollen lymph nodes in neck, swollen gums that later blistered, swollen tongue that blistered, oral thrush, sore muscles, no energy, fatigue, sore throat and caught. On 26Apr2021, 5 days after the vaccine, the patient woke up with extreme nausea, exhaustion and no energy and there was no fever, stomach ache or rash. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore arm at injection site, swollen lymph nodes in neck, swollen gums that later blistered, swollen tongue that blistered, oral thrush, sore muscles, no energy, fatigue, sore throat, extreme nausea and exhaustion was not resolved at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Oral candidiasis, Oropharyngeal pain, Swollen tongue
Clinical narrative: Extreme nausea; Exhaustion; Swollen lymph nodes in neck; Swollen gums; Swollen gums that later blistered; Swollen tongue; Swollen tongue that blistered; Oral thrush; Sore muscles; No energy; Fatigue; Sore throat; Sore arm at injection site; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0162) via an unspecified route of administration in the left arm on 21Apr2021 at 13:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included stevens johnson syndrome. The patient had no known allergies. Concomitant medications included amfetamine aspartate/ amfetamine sulfate/ dexamfetamine saccharate/ dexamfetamine sulfate (ADDERALL), paracetamol (TYLENOL) and vitamins (MANUFACTURER UNKNOWN) (unspecified); all from unknown dates for unknown indications and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, the patient experienced sore arm at injection site and had no symptoms for 48 hours after the vaccination. After 48 hours, on 23Apr2021, the patient experienced swollen lymph nodes in neck, swollen gums that later blistered, swollen tongue that blistered, oral thrush, sore muscles, no energy, fatigue, sore throat and caught. On 26Apr2021, 5 days after the vaccine, the patient woke up with extreme nausea, exhaustion and no energy and there was no fever, stomach ache or rash. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore arm at injection site, swollen lymph nodes in neck, swollen gums that later blistered, swollen tongue that blistered, oral thrush, sore muscles, no energy, fatigue, sore throat, extreme nausea and exhaustion was not resolved at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Tongue blistering, Vaccination site pain
Clinical narrative: Extreme nausea; Exhaustion; Swollen lymph nodes in neck; Swollen gums; Swollen gums that later blistered; Swollen tongue; Swollen tongue that blistered; Oral thrush; Sore muscles; No energy; Fatigue; Sore throat; Sore arm at injection site; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0162) via an unspecified route of administration in the left arm on 21Apr2021 at 13:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included stevens johnson syndrome. The patient had no known allergies. Concomitant medications included amfetamine aspartate/ amfetamine sulfate/ dexamfetamine saccharate/ dexamfetamine sulfate (ADDERALL), paracetamol (TYLENOL) and vitamins (MANUFACTURER UNKNOWN) (unspecified); all from unknown dates for unknown indications and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, the patient experienced sore arm at injection site and had no symptoms for 48 hours after the vaccination. After 48 hours, on 23Apr2021, the patient experienced swollen lymph nodes in neck, swollen gums that later blistered, swollen tongue that blistered, oral thrush, sore muscles, no energy, fatigue, sore throat and caught. On 26Apr2021, 5 days after the vaccine, the patient woke up with extreme nausea, exhaustion and no energy and there was no fever, stomach ache or rash. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore arm at injection site, swollen lymph nodes in neck, swollen gums that later blistered, swollen tongue that blistered, oral thrush, sore muscles, no energy, fatigue, sore throat, extreme nausea and exhaustion was not resolved at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Piloerection, Pruritus
Clinical narrative: Back started scratching; Goosebumps frequently; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9266) via an unspecified route of administration on 20Feb2021 at 15:30 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included chlortalidone (CHLORTHALIDONE) and olmesartan (MANUFACTURER UNKNOWN); for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On an unknown date in 2021, a few weeks after the vaccination, the patient experienced back started scratching uncontrollably every day and goosebumps frequently. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the event back started scratching and goosebumps frequently was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Hypoaesthesia, Paraesthesia, Paraesthesia oral, Rash
Clinical narrative: Metalic taste in mouth; Rash in arm; Numbness; Strong tingling feeling in left nostril and left side of mouth; Strong tingling feeling in left nostril and left side of mouth; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0161) via an unspecified route of administration in the left arm on 12Apr2021 at 14:45 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergies to sulfa drugs (sulfonamide allergy). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other vaccines within two weeks prior to the vaccination. Concomitant medications were not reported. The patient previously took codeine (MANUFACTURER UNKNOWN) and experienced drug allergy. On 12Apr2021 at 16:00, the patient experienced metallic taste in mouth, rash in arm, numbness and strong tingling feeling in left nostril and left side of mouth. The patient reported that it had been two weeks and she still feel the metal taste and tingling sensation in nose and mouth (strongly). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events metallic taste in mouth, rash in arm, numbness and strong tingling feeling in left nostril and left side of mouth were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Nausea, Vertigo positional
Clinical narrative: Benign paroxysmal positional vertigo; Slight nausea; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ENG207) via an unspecified route of administration in the left arm on 19Mar2021 at 08:45 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had known allergies to shellfish. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN), triamterene (MANUFACTURER UNKNOWN) and acetylsalicylic acid (ASPIRIN); all taken for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 26Feb2021 at 14:00 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. On 11Apr2021 at 11:00, the patient experienced benign paroxysmal positional vertigo, including slight nausea. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measure was taken as a result of benign paroxysmal positional vertigo, including slight nausea included treatment with exercise similar to epley manoeuvre. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events benign paroxysmal positional vertigo and slight nausea was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Aphonia, Dysphonia
Clinical narrative: Lost voice/wraspy voice; Lost voice/wraspy voice; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 21Apr2021 at 11:45 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included SLE (lupus), high blood pressure, anxiety and known allergies to latex, pineapple, banana and berries. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included azathioprine (IMURAN), hydroxychloroquine phosphate (PLAQUENIL), valsartan (MANUFACTURER UNKNOWN), sertraline hydrochloride (ZOLOFT) and trazodone (MANUFACTURER UNKNOWN); all for unspecified indication, from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on an unknown date in Mar2021 at 13:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient previously received codeine (MANUFACTURER UNKNOWN) on  an unknown date for an unknown indication and experienced drug allergy. On 21Apr2021 at 15:00, after second dose (in afternoon), the patient experienced lost voice/wraspy voice. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events lost voice/wraspy voice were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling
Clinical narrative: ''My'' entire left arm swelled a LOT. From the shoulder to ''my'' wrist.; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in Apr2021 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included lupus, ankylosing spondylitis, crohn's disease and known allergies to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included adalimumab (HUMIRA) for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On an unknown date in Apr2021, the patient experienced her entire left arm swelled a lot, from the shoulder to her wrist. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were not taken as a result of the events. The clinical outcome of the event entire left arm swelled a lot, from the shoulder to wrist was recovering at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 38.0
Sex: U
Vaccine: COVID19
Symptoms: Thirst
Clinical narrative: Excessive thirst; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old patient with unspecified gender received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Apr2021 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included obesity. The patient had no known allergies. Concomitant medications included citalopram (MANUFACTURER UNKNOWN), linum usitatissimum seed oil (flaxseed oil) (MANUFACTURER UNKNOWN) and prenatal vitamins (MANUFACTURER UNKNOWN) used for an unknown indication from an unknown date and unknown if ongoing. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 24Apr2021, the patient experienced excessive thirst. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event excessive thirst was not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Cyanosis, Peripheral swelling
Clinical narrative: Ring finger on the right hand felt strange. It started to swell; Ring finger on the right hand felt strange. It started to swell and turn purple; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 23Apr2021 at 14:30 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history included MTHFR (Methylenetetrahydrofolate reductase), celiac disease, pneumonia and allergy to wheat. Concomitant medication included supplements (unspecified) for an unknown indication from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took prochlorperazine maleate (COMPAZINE) and sulfamethoxazole/ trimethoprim (BACTRIM) and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 02Apr2021 at 14:00 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. On 25Apr2021 (also reported as Sunday) at 19:00, in the evening when cooking dinner, the patient felt ring finger on the right hand felt strange and it started to swell and turn purple. The patient was concerned about blood clots. The events resulted in emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included rest and ice. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events ring finger on the right hand felt strange and it started to swell and turn purple was resolved with sequelae (also reported as recovered with lasting effects) on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Myalgia, Pain in extremity
Clinical narrative: Bilateral intense pain in both upper quadriceps; Bilateral intense pain  in both wrists; Bilateral intense pain in both shoulders; Bilateral intense pain in both psoas muscles; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the right arm on 28Mar2021 at 10:15 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes and multiple spinal fusions. The patient had known allergies to fluoroquinolones such as ciprofloxacin(MANUFACTURER UNKNOWN) which was taken for an unknown indication on an unknown date and experienced drug allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient received medications within 2weeks of vaccination which was unspecified. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 06Mar2021 at 12:15 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. On 30Mar2021, the patient experienced bilateral intense pain in both wrists, bilateral intense pain in both shoulders, bilateral intense pain in both upper quadriceps and psoas muscles. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of wrist pain, shoulder pain, pain in upper quadriceps and psoas muscle pain and included treatment with physical therapy. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events bilateral intense pain in both wrists, bilateral intense pain in both shoulders, bilateral intense pain in both upper quadriceps and psoas muscles was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Cough, Dyspnoea, Feeling abnormal, Feeling hot
Clinical narrative: Pain in arm; Warm to the touch; Body aches mostly in lower body; Joint pain; Runny nose; Cough; Easily out of breath; Also brought back brain fog; Changes in taste; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Apr2021 at 09:15 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome(IBS), migraine, COVID-19 and the patient had known allergies to decongestants, latex and several food allergies. Prior to vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levocetirizine dihydrochloride (XYZAL) from an unknown date for an unknown indication and unknown if ongoing. On 06Apr2021 at 17:00, the patient experienced pain in arm and warm to the touch, body aches mostly in lower body, joint pain, runny nose, cough and easily out of breath. The patient also felt brain fog and changes in taste. The patient started feeling bad that evening and felt as though she had COVID-19 again the day after vaccine and just tired with brain fog on the day after that. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events pain in arm and warm to the touch, body aches mostly in lower body, joint pain, runny nose, cough, easily out of breath, foggy feeling in head and taste changed were recovered on an unknown date in Apr2021.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pain in extremity, Rhinorrhoea, Taste disorder
Clinical narrative: Pain in arm; Warm to the touch; Body aches mostly in lower body; Joint pain; Runny nose; Cough; Easily out of breath; Also brought back brain fog; Changes in taste; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Apr2021 at 09:15 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome(IBS), migraine, COVID-19 and the patient had known allergies to decongestants, latex and several food allergies. Prior to vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levocetirizine dihydrochloride (XYZAL) from an unknown date for an unknown indication and unknown if ongoing. On 06Apr2021 at 17:00, the patient experienced pain in arm and warm to the touch, body aches mostly in lower body, joint pain, runny nose, cough and easily out of breath. The patient also felt brain fog and changes in taste. The patient started feeling bad that evening and felt as though she had COVID-19 again the day after vaccine and just tired with brain fog on the day after that. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events pain in arm and warm to the touch, body aches mostly in lower body, joint pain, runny nose, cough, easily out of breath, foggy feeling in head and taste changed were recovered on an unknown date in Apr2021.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.